Dementia and Alzheimer's Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region and Competition, 2020-2030F

Description

The Global Dementia and Alzheimer's Disease Treatment Market was valued at USD 12.17 Billion in 2024 and is projected to reach USD 17.62 Billion by 2030, growing at a CAGR of 6.56%. As global populations age, the prevalence of Alzheimer's disease and related dementias is rising significantly, fueling demand for more effective therapeutic interventions. While the market has traditionally been driven by symptomatic treatments such as cholinesterase inhibitors and NMDA receptor antagonists, new advancements in neuroscience are now paving the way for disease-modifying therapies. These newer approaches aim to address the biological mechanisms of the disease, including beta-amyloid plaques and tau protein tangles. Pharmaceutical companies and research institutions are investing heavily in this direction. Despite the progress, the field faces ongoing hurdles due to the complexity of the disease and the high rate of failure in clinical trials, which continue to challenge drug development and commercialization efforts.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 12.17 Billion
Market Size 2030	USD 17.62 Billion
CAGR 2025-2030	6.56%
Fastest Growing Segment	Cholinergic/ Cholinesterase (ChE) Inhibitors
Largest Market	North America

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare industry-generating more than USD 4 trillion in annual revenues-serves as a major catalyst for growth in the dementia and Alzheimer's treatment market. Key contributors include pharmaceuticals and biotechnology, which together account for nearly USD 850 billion, and diagnostics and medical technology, generating over USD 400 billion. With improved life expectancy and better access to medical services, healthcare systems are increasingly prioritizing age-related neurodegenerative diseases. This trend is driving investment in research and development focused on Alzheimer's and dementia therapies, and is supported by growing global awareness and demand for effective long-term treatment options.

Key Market Challenges

High Cost of Treatment and Care

The elevated cost of treatment and associated care services represents a key barrier in the dementia and Alzheimer's disease treatment market. The financial strain extends beyond pharmaceutical expenditures, encompassing long-term care, specialized nursing, and daily assistance-all of which are typically not fully covered by public health insurance in many regions. The introduction of innovative disease-modifying therapies, while clinically promising, adds to cost concerns due to their complex production, monitoring requirements, and regulatory demands. These high costs challenge the affordability and accessibility of new treatments, particularly in low- and middle-income countries with constrained healthcare budgets and limited infrastructure for administering advanced therapeutics.

Key Market Trends

Advancement in Tau-Targeted Therapies

An important trend shaping the market is the increasing focus on tau-targeted therapies as an alternative or complement to amyloid-focused treatments. Research has shown that abnormal accumulation of tau proteins, which form neurofibrillary tangles in the brain, is closely associated with cognitive decline in Alzheimer's patients. As traditional therapies targeting amyloid plaques have delivered limited results, pharmaceutical companies are shifting attention toward tau as a therapeutic target. Innovations such as ACI-35-a liposome-based vaccine targeting phosphorylated tau-have shown promising safety and tolerability profiles in clinical trials. The pipeline now includes various modalities like monoclonal antibodies, antisense oligonucleotides, and small molecule inhibitors aimed at mitigating tau pathology. These advancements are expected to drive future breakthroughs in disease-modifying treatments.

Key Market Players

Merz Pharma GmbH & Co. KGaA
Novartis AG
Pfizer, Inc.
Ono Pharmaceutical Co., Ltd.
Johnson & Johnson Services, Inc.
H. Lundbeck A/S
F. Hoffmann-La Roche Ltd.
AbbVie Inc.
Eli Lilly and Company
Corium, Inc.

Report Scope

In this report, the Global Dementia and Alzheimer's Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dementia and Alzheimer's Disease Treatment Market, By Drug Class:

Cholinergic/ Cholinesterase (ChE) Inhibitors
Memantine
Combination Drugs
Others

Dementia and Alzheimer's Disease Treatment Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Dementia and Alzheimer's Disease Treatment Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dementia and Alzheimer's Disease Treatment Market.

Available Customizations:

Global Dementia and Alzheimer's Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Dementia and Alzheimer's Disease Treatment Market

5. Global Dementia and Alzheimer's Disease Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, Combination Drugs, Others)
- 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Dementia and Alzheimer's Disease Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Distribution Channel
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Dementia and Alzheimer's Disease Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Class
    - 6.3.1.2.2. By Distribution Channel
- 6.3.2. Mexico Dementia and Alzheimer's Disease Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Class
    - 6.3.2.2.2. By Distribution Channel
- 6.3.3. Canada Dementia and Alzheimer's Disease Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Class
    - 6.3.3.2.2. By Distribution Channel

7. Europe Dementia and Alzheimer's Disease Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Distribution Channel
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Dementia and Alzheimer's Disease Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Class
    - 7.3.1.2.2. By Distribution Channel
- 7.3.2. Germany Dementia and Alzheimer's Disease Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Class
    - 7.3.2.2.2. By Distribution Channel
- 7.3.3. United Kingdom Dementia and Alzheimer's Disease Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Distribution Channel
- 7.3.4. Italy Dementia and Alzheimer's Disease Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Class
    - 7.3.4.2.2. By Distribution Channel
- 7.3.5. Spain Dementia and Alzheimer's Disease Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Class
    - 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Dementia and Alzheimer's Disease Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Distribution Channel
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Dementia and Alzheimer's Disease Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Class
    - 8.3.1.2.2. By Distribution Channel
- 8.3.2. India Dementia and Alzheimer's Disease Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Class
    - 8.3.2.2.2. By Distribution Channel
- 8.3.3. South Korea Dementia and Alzheimer's Disease Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Class
    - 8.3.3.2.2. By Distribution Channel
- 8.3.4. Japan Dementia and Alzheimer's Disease Treatment Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Class
    - 8.3.4.2.2. By Distribution Channel
- 8.3.5. Australia Dementia and Alzheimer's Disease Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Class
    - 8.3.5.2.2. By Distribution Channel

9. South America Dementia and Alzheimer's Disease Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Distribution Channel
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Dementia and Alzheimer's Disease Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Class
    - 9.3.1.2.2. By Distribution Channel
- 9.3.2. Argentina Dementia and Alzheimer's Disease Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Class
    - 9.3.2.2.2. By Distribution Channel
- 9.3.3. Colombia Dementia and Alzheimer's Disease Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Class
    - 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Dementia and Alzheimer's Disease Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Distribution Channel
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Dementia and Alzheimer's Disease Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Class
    - 10.3.1.2.2. By Distribution Channel
- 10.3.2. Saudi Arabia Dementia and Alzheimer's Disease Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Class
    - 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Dementia and Alzheimer's Disease Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Class
    - 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Dementia and Alzheimer's Disease Treatment Market: SWOT Analysis

15. Porters Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. Merz Pharma GmbH & Co. KGaA
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. Novartis AG
16.3. Pfizer, Inc.
16.4. Ono Pharmaceutical Co., Ltd.
16.5. Johnson & Johnson Services, Inc.
16.6. H. Lundbeck A/S
16.7. F. Hoffmann-La Roche Ltd.
16.8. AbbVie Inc.
16.9. Eli Lilly and Company
16.10. Corium, Inc.